

What is claimed:

1. A method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

5

10

2. The method of claim 1, wherein the antibody is a monoclonal antibody.

15

3. The method of claim 1, wherein the antibody is selected from the group consisting of PA8 (ATCC Accession No. HB-12605), PA9 (ATCC Accession No. HB-12606), PA10 (ATCC Accession No. HB-12607), PA11 (ATCC Accession No. HB-12608), PA12 (ATCC Accession No. HB-12609), and PA14 (ATCC Accession No. HB-12610).

20

4. The method of claim 1, wherein the antibody is PA14 (ATCC Accession No. HB-12610).

25

5
The method of claim 1, wherein the subject's HIV-1 viral load is reduced to 33% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

30

6. The method of claim 1, wherein the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

35

40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000

Sub.B1

Sub.B2

Sub B2

7. The method of claim 1, wherein the reduction of the subject's HIV-1 viral load is sustained for a period of time.

5 8. The method of claim 7, wherein the period of time is at least one day.

9. The method of claim 7, wherein the period of time is at least three days.

10 10. The method of claim 7, wherein the period of time is at least seven days.

15 11. The method of claim 1, wherein the effective amount of the antibody is between about 1mg and about 50mg per kg body weight of the subject.

20 12. The method of claim 11, wherein the effective amount of the antibody is between about 2mg and about 40mg per kg body weight of the subject.

25 13. The method of claim 12, wherein the effective amount of the antibody is between about 3mg and about 30mg per kg body weight of the subject.

14. The method of claim 13, wherein the effective amount of the antibody is between about 4mg and about 20mg per kg body weight of the subject.

30 15. The method of claim 14, wherein the effective amount of the antibody is between about 5mg and about 10mg per kg body weight of the subject.

35 16. The method of claim 1, wherein the antibody is

administered at least once per day.

17. The method of claim 1, wherein the antibody is administered daily.

5

18. The method of claim 1, wherein the antibody is administered every other day.

10 19. The method of claim 1, wherein the antibody is administered every 6 to 8 days.

20. The method of claim 1, wherein the antibody is administered weekly.

15 21. The method of claim 1, wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.

20 22. The method of claim 1, wherein the subject is a human being and the antibody is a humanized antibody.

DRAFT - DRAFT